CA2745618C - Anti-ferroportin 1 monoclonal antibodies and uses thereof - Google Patents

Anti-ferroportin 1 monoclonal antibodies and uses thereof Download PDF

Info

Publication number
CA2745618C
CA2745618C CA2745618A CA2745618A CA2745618C CA 2745618 C CA2745618 C CA 2745618C CA 2745618 A CA2745618 A CA 2745618A CA 2745618 A CA2745618 A CA 2745618A CA 2745618 C CA2745618 C CA 2745618C
Authority
CA
Canada
Prior art keywords
seq
antigen
monoclonal antibody
subject
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2745618A
Other languages
English (en)
French (fr)
Other versions
CA2745618A1 (en
Inventor
Donmienne Doen Mun Leung
Peng Luan
Joseph Vincent Manetta
Ying Tang
Derrick Ryan Witcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2745618A1 publication Critical patent/CA2745618A1/en
Application granted granted Critical
Publication of CA2745618C publication Critical patent/CA2745618C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2745618A 2008-12-05 2009-12-01 Anti-ferroportin 1 monoclonal antibodies and uses thereof Expired - Fee Related CA2745618C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12007608P 2008-12-05 2008-12-05
US61/120,076 2008-12-05
US23981809P 2009-09-04 2009-09-04
US61/239,818 2009-09-04
PCT/US2009/066187 WO2010065496A1 (en) 2008-12-05 2009-12-01 Anti-ferroportin 1 monoclonal antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CA2745618A1 CA2745618A1 (en) 2010-06-10
CA2745618C true CA2745618C (en) 2014-06-10

Family

ID=41683589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2745618A Expired - Fee Related CA2745618C (en) 2008-12-05 2009-12-01 Anti-ferroportin 1 monoclonal antibodies and uses thereof

Country Status (25)

Country Link
EP (1) EP2373335B1 (enExample)
JP (1) JP5713917B2 (enExample)
KR (1) KR101353117B1 (enExample)
CN (1) CN102238962B (enExample)
AR (1) AR074398A1 (enExample)
AU (1) AU2009322587B2 (enExample)
BR (1) BRPI0922288A2 (enExample)
CA (1) CA2745618C (enExample)
CY (1) CY1117355T1 (enExample)
DK (1) DK2373335T3 (enExample)
EA (1) EA020472B1 (enExample)
ES (1) ES2566343T3 (enExample)
HR (1) HRP20160302T1 (enExample)
HU (1) HUE028585T2 (enExample)
IL (1) IL212731A0 (enExample)
MX (1) MX2011005939A (enExample)
NZ (1) NZ592545A (enExample)
PA (1) PA8849601A1 (enExample)
PL (1) PL2373335T3 (enExample)
SG (1) SG171960A1 (enExample)
SI (1) SI2373335T1 (enExample)
TW (1) TW201023891A (enExample)
UA (1) UA104741C2 (enExample)
WO (1) WO2010065496A1 (enExample)
ZA (1) ZA201103941B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014027905A2 (pt) * 2012-05-14 2017-06-27 Genentech Inc anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
WO2019213016A1 (en) 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
CN110806486B (zh) * 2019-11-23 2023-03-21 中南大学湘雅三医院 Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN113980987A (zh) * 2021-12-06 2022-01-28 上海市农业科学院 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) * 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
IT1319221B1 (it) * 2000-10-17 2003-09-26 Antonello Pietrangelo Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria.
EP2803675A3 (en) * 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use

Also Published As

Publication number Publication date
WO2010065496A1 (en) 2010-06-10
AR074398A1 (es) 2011-01-12
JP2012510814A (ja) 2012-05-17
JP5713917B2 (ja) 2015-05-07
CA2745618A1 (en) 2010-06-10
AU2009322587A1 (en) 2011-07-28
EA201170764A1 (ru) 2011-12-30
HUE028585T2 (en) 2016-12-28
HK1158977A1 (zh) 2012-07-27
KR20110084996A (ko) 2011-07-26
UA104741C2 (uk) 2014-03-11
AU2009322587B2 (en) 2013-09-26
CN102238962A (zh) 2011-11-09
SG171960A1 (en) 2011-07-28
KR101353117B1 (ko) 2014-02-17
EP2373335A1 (en) 2011-10-12
MX2011005939A (es) 2011-06-27
IL212731A0 (en) 2011-07-31
TW201023891A (en) 2010-07-01
PL2373335T3 (pl) 2016-08-31
SI2373335T1 (sl) 2016-04-29
HRP20160302T1 (hr) 2016-04-22
NZ592545A (en) 2012-12-21
EA020472B1 (ru) 2014-11-28
ES2566343T3 (es) 2016-04-12
BRPI0922288A2 (pt) 2018-08-28
DK2373335T3 (en) 2016-05-02
CN102238962B (zh) 2014-02-12
ZA201103941B (en) 2012-11-28
PA8849601A1 (es) 2010-07-27
EP2373335B1 (en) 2016-02-24
CY1117355T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
US8679497B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
KR102453227B1 (ko) 항-axl 길항성 항체
JP5896993B2 (ja) ヒトｇｄｆ８に対する抗体
KR101414847B1 (ko) 페길화된 Ａβ ＦＡＢ
US20220195054A1 (en) Anti-Axl Antagonistic Antibodies
KR102366853B1 (ko) Cd47 항체 및 사이토카인을 포함하는 융합 단백질
JP7110369B2 (ja) 抗ｐｄ－１抗体及びその用途
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
AU2009322587B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
TW201609805A (zh) 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
EP3145544B1 (en) Ang2 antibodies
KR20260013489A (ko) TrkA 항체 및 이의 용도
US20220242943A1 (en) Anti- pdgf-b antibodies and methods of use for treating pulmonary arterial hypertension (pah)
HK1158977B (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
WO2025113639A1 (zh) 抗gdf15的抗体及其方法和用途
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181203